share_log

Stifel Downgrades Angion Biomedica to Hold, Lowers Price Target to $1.5

Stifel Downgrades Angion Biomedica to Hold, Lowers Price Target to $1.5

Stifel将Angion Biomedica的评级下调至持有,将目标股价下调至1.5美元
Benzinga Real-time News ·  2022/06/30 06:08

Stifel analyst Annabel Samimy downgrades Angion Biomedica (NASDAQ:ANGN) from Buy to Hold and lowers the price target from $5 to $1.5.

Stifel分析师安娜贝尔·萨米米将Angion Biomedica(纳斯达克股票代码:ANGN)的评级从买入下调至持有,并将目标股价从5美元下调至1.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发